BioSignals
In this episode of BioSignals, host Vince Wong sits down with Dr. Ruth Gimeno, Group Vice President of Diabetes, Obesity & Cardiometabolic Research and Early Clinical Development at Eli Lilly and Company. Dr. Gimeno shares her perspective as a physician-scientist and biotech leader working at the forefront of therapeutic innovation. The conversation explores how complex biological discoveries move from the lab into clinical development, and ultimately toward real-world impact for patients. From breakthroughs in obesity and cardiometabolic disease to the challenges of translating science into medicine, Dr. Gimeno discusses what it takes to turn early insight into life-changing therapies.
7 jaksot
Kommentit
0Ole ensimmäinen kommentoija
Rekisteröidy nyt ja liity BioSignals-yhteisöön!